百济神州(06160.HK)合作产品「安加维」於中国正式开启商业化上市
百济神州(06160.HK)公布,地舒单抗注射液「安加维」於中国正式开启商业化上市,产品用於治疗骨巨细胞瘤。公司表示,是继百济神州和安进於今年1月达成全球肿瘤战略合作後,百济神州首款正式在中国开启商业化上市的由安进公司生产的药品。
公司中国区总经理兼总裁吴晓滨表示,安加维在中国正式开启商业化上市,标志着百济神州与安进公司的战略合作迈进了一个新的里程碑。他指,公司在中国的商业化团队目前有1,200多名员工。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.